Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2007

View Archived Issues

Agomelatine plus acebutolol improves sleep in Smith-Magenis syndrome

Novel agents for treating dermatological disorders disclosed in recent patents

Novel magnetic resonance imaging agents reported in recent GE Healthcare patent

Amgen announces third quarter 2007 results

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

Pharmacokinetic results for ECO-4601 available

Similar pain relief seen with ALO-01 and Kadian in osteoarthritis patients

Lexatumumab safe when combined with chemotherapy in phase Ib study

Targeting LINGO-1: a novel strategy for the treatment of neurodegenerative diseases

In vivo antitumor activity by CCT-129202, a novel Aurora kinase inhibitor

Novel IGF-IR inhibitor reported by Abbott at the AACR-NCI-EORTC meeting

JNJ-26481585 shows promising preclinical efficacy in cancer models

Cambridge Antibody Technology changes its name to MedImmune

Patient enrollment completed in phase IIa trial of nalbuphine extended-release tablet

FDA approves Supratek's IND application for SP-1049C

Xanthus' Xanafide is granted orphan drug designation by the European Commission

AVI presents updates on clinical studies of AVI-4658 for Duchenne muscular dystrophy

GRC-3886 to undergo further phase II study following favorable partial response from the FDA

FDA recommends suspension of clinical studies with higher doses of TAK-475

Thallion has yet to reach agreement with the FDA over clinical trial design for Shigamabs

ChemGenex restructures the company to focus on its clinical-stage cancer portfolio

Coley initiates phase I study of CPG-52364 for treatment of systemic lupus erythematosus

MGI and Helsinn submit supplemental NDA for Aloxi capsules for oral administration

FDA grants marketing approval to Genzyme Corporation's Epicel

Concerta granted Japanese approval for pediatric attention deficit hyperactivity disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...